The introduction of targeted agents into modern cancer therapy pursued the goal of molecularly more specific, and thereby more effective

 

Abstract

The introduction of targeted agents into modern cancer therapy pursued the goal of molecularly more specific, and thereby more effective and safer, therapies. Paradoxically, however, several toxicities were brought to greater attention, among these not only cardiac but also vascular toxicities. The latter reach far beyond venous thromboembolism and include a broad spectrum of presentations based on the vascular territories and pathomechanisms involved, including abnormal vascular reactivity, acute thrombosis, or accelerated atherosclerosis. This article provides an overview of the most common presentations and their management strategies.

PMID: 31587779 [PubMed - indexed for MEDLINE]

00:40

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

00:40

In reply to this message

pubmed: ctoall&ca or conall

Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif //www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www3.us.elsevierhealth.com-extractor-graphics-pubmed-clinicslogo.gif Related Articles

Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks.

Cardiol Clin. 2019 Nov;37(4):355-363

Authors: Alvarez-Cardona J, Lenihan DJ